PEA vs Pentosan (Joint Pain)
A side-by-side research comparison of PEA and Pentosan (Joint Pain) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | PEA | Pentosan (Joint Pain) |
|---|---|---|
| Full name | Palmitoylethanolamide | Pentosan Polysulfate Sodium (Cartrophen) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Dietary supplement (medical food in EU) | FDA Approved (interstitial cystitis) / Veterinary approved |
| Mechanism | Activates PPARĪ± nuclear receptors for anti-inflammatory gene transcription. Inhibits mast cell degranulation. Enhances endocannabinoid tone by inhibiting FAAH (increasing anandamide). Desensitizes TRPV1 pain channels via allosteric modulation. | Inhibits matrix metalloproteinases (MMPs) and aggrecanases that degrade cartilage. Stimulates hyaluronic acid production by synoviocytes. Promotes proteoglycan synthesis by chondrocytes. Reduces subchondral bone remodeling via anti-inflammatory effects. |
| Molecular weight | 299.49 Da | ~4000-6000 Da (average) |
| Half-life | ~1-2 hours (micronized form extends effects) | ~24 hours |
| Bioavailability | ~20% (standard); improved with micronized/ultra-micronized forms | ~6% oral; ~100% subcutaneous |
| Typical dose | 300-1200 mg | 2-3 mg/kg SC (veterinary extrapolation) or 100mg oral 3x/day |
| Frequency | 2-3x daily | Weekly SC injections (4-6 course) or daily oral |
| Route | Oral (micronized preferred) | Subcutaneous injection or oral capsule |
PEA reported benefits
- Chronic pain reduction
- Neuropathic pain relief
- Anti-inflammatory (mast cell stabilization)
- No tolerance or dependence
- Neuroprotection
- Safe with other medications
Pentosan (Joint Pain) reported benefits
- Cartilage protection and repair
- Reduced joint inflammation
- Improved synovial fluid
- Disease-modifying (not just symptomatic)
- Reduced bone marrow edema
- Alternative to corticosteroid injections
Related comparisons
Research and educational reference only. Not medical advice.